Mérieux Equity Partners teams up with ICG to acquire leading Italian generic company, DOC Generici
DOC Generici is Italy’s largest independent generic pharmaceutical company.
Inscripta expands Series C Financing Round to $105.5 million
Existing investors have agreed to contribute an additional $20 million to its previously announced Series C funding round.
Merieux Equity Partners to enter in exclusive negotiations for the sale of their stake in Amplitude Laser Group to L-GAM
Amplitude Laser Group has transformed itself into a global leader with a truly international footprint.
Xeris Pharmaceuticals presents new Clinical and Economic Impact Data on its Developmental Ready-to-use Glucagon
Data from a Phase 2 study in congenital hyperinsulinism (CHI) reinforce the utility of Xeris’ ready-to-use, liquid-stable Glucagon.
LNA Santé acquires the Moulin Vert Rehabilitation Center
The Moulin Vert facility specializes in the treatment of respiratory diseases and heart disorders
Xeris Pharmaceuticals doses first patient in Phase 2 trial evaluating its ready-to-use Glucagon to address Exercise-Induced Hypogycemia
Xeris has begun dosing Type 1 diabetes patients with its stable liquid Glucagon.
Ivantis announces 24-month results of Landmark Clinical Trial
International multi-center study compares effectiveness of the Hydrus® Microstent to two Glaukos iStent® Trabecular Micro-Bypass stents in standalone glaucoma.
Biobest's PMV®-01: First Vaccine against PepMV authorized in North America
PMV®-01 is the first plant vaccine against Pepino Mosaic Virus (PepMV) in tomato authorized by EPA and PMRA.